Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

CHMP recommends eight new medicines for EU approval

CHMP recommends eight new medicines for EU approval The positive opinions include Bristol Myers Squibb’s CAR T therapy Abecma (idecabtagene vicleucel) as a potential new treatment for highly refractory multiple myeloma.

BMS’s oral AML therapy Onureg receives EU approval

BMS’s oral AML therapy Onureg receives EU approval The European Commission has granted Bristol Myers Squibb’s (BMS) Onureg a full marketing authorisation as maintenance therapy for adult patients with acute myeloid leukaemia (AML). ... aggressive blood cancer,” said Noah Berkowitz, senior vice

BMS and Eisai to collaborate in deal worth up to $3.1bn

BMS and Eisai to collaborate in deal worth up to $3.1bn Bristol Myers Squibb (BMS) and Eisai have entered a strategic collaboration focused on the development of Eisai’s antibody drug conjugate (ADC) candidate MORAb-202. ... This global collaboration with Eisai is an important strategic fit for Bristol

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma EHA). The data comes from the phase 3 MAIA trial, which evaluated Darzalex (daratumumab) plus Bristol Myers Squibb’s Revlimid (lenalidomide) and dexamethasone compared with Revlimid and dexamethasone alone in newly

BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients

BMS, Acceleron’s Reblozyl shows new improvements for beta thalassemia patients Bristol Myers Squibb (BMS) and Acceleron have revealed the first data from a phase 2 study of its erythroid maturation agent Reblozyl in adults with non-transfusion dependent (NTD) beta thalassemia. ... non-transfusion dependent disease who face a range

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...